



## **First sales of Flu Vaccines Produced on Valneva's EB66<sup>®</sup> Cell-Line**

### **Valneva to begin receiving royalties for an EB66<sup>®</sup>-based human vaccine in 2016**

**Lyon (France), June 13, 2016** - Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, announces today that GlaxoSmithKline (GSK) in collaboration with one of its partners has for the first time supplied pre-pandemic influenza vaccines based on Valneva's EB66<sup>®</sup> cell line.